SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

REDMOND, Wash., July 17, 2026 /PRNewswire/ -- SystImmune Inc. (SystImmune) today announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's National Medical Products Administration (NMPA) for iza-bren (izalontamab...